Rexahn Pharmaceuticals

Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The Company's clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2001
Size (employees)
20 (est)
Website
rexahn.com
Rexahn Pharmaceuticals was founded in 2001 and is headquartered in Rockville, US

Rexahn Pharmaceuticals Office Locations

Rexahn Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
15245 Shady Grove Road

Rexahn Pharmaceuticals Financials and Metrics

Rexahn Pharmaceuticals Financials

USD

Net income (FY, 2016)

(9.3 m)

EBIT (FY, 2016)

(16.4 m)

Market capitalization (13-Dec-2017)

55.8 m

Cash (31-Dec-2016)

11.6 m
Rexahn Pharmaceuticals's current market capitalization is $55.8 m.
USDFY, 2015FY, 2016

R&D expense

12.1 m10.1 m

General and administrative expense

6.1 m6.3 m

Operating expense total

18.3 m16.4 m

EBIT

(18.3 m)(16.4 m)
USDQ3, 2013Q1, 2014

R&D expense

781.3 k1.3 m

General and administrative expense

932.8 k1.4 m

Operating expense total

1.8 m2.8 m

EBIT

(1.8 m)(2.8 m)
USDFY, 2015FY, 2016

Cash

10.2 m11.6 m

Inventories

1.2 m608.5 k

Current Assets

24.7 m20.9 m

Total Assets

24.8 m21 m
USDQ3, 2013Q1, 2014

Cash

14.9 m40.1 m

Current Assets

15.5 m40.9 m

Total Assets

16.1 m41.1 m

Accounts Payable

750.2 k878.5 k
USDFY, 2015FY, 2016

Net Income

(14.4 m)(9.3 m)

Depreciation and Amortization

27.5 k32.9 k

Accounts Payable

202 k(778.8 k)

Cash From Operating Activities

(17.4 m)(13.2 m)
USDQ3, 2013Q1, 2014

Net Income

(6.8 m)(14.6 m)

Depreciation and Amortization

28.2 k9 k

Accounts Payable

(101.6 k)(55.3 k)

Cash From Operating Activities

(5.7 m)(2.6 m)
Y, 2016

Financial Leverage

1.2 x
Show all financial metrics

Rexahn Pharmaceuticals Operating Metrics

FY, 2016

Phase II Trials

3

Phase Preclinical

1

Patents and Patent Applications

7

Patent Portfolios

3
Show all operating metrics

Rexahn Pharmaceuticals Market Value History

Rexahn Pharmaceuticals's Web-traffic and Trends

Rexahn Pharmaceuticals Company Life and Culture

You may also be interested in